Actinium Pharmaceuticals, Inc. (FRA:7AY1)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.26M -41.1% |
| Revenue (ttm) | 30.71M |
| Net Income | 9.90M |
| EPS | 0.31 |
| Shares Out | n/a |
| PE Ratio | 2.75 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.8450 |
| Previous Close | 0.9080 |
| Day's Range | 0.8450 - 0.8450 |
| 52-Week Range | 0.6340 - 1.5000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody... [Read more]
News
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advance...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
Actinium Pharmaceuticals Quarterly report: Q2 2026
Actinium Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 7, 2026.
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026
Actinium Pharmaceuticals (ATNM) on June 2 presented new preclinical data on ATNM-400 in non-small cell lung cancer, or NSCLC, at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual…
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater th...
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide (Er...
Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer
Actinium Pharmaceuticals (ATNM) announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug dev...
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical thro...
Actinium Pharmaceuticals presents new radiochemistry data at SNMMI
Actinium Pharmaceuticals (ATNM), on May 31, presented new radiochemistry data at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting taking place in Los Angeles, California. High...
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidat...
Actinium Pharmaceuticals receives two patent allowances from CIPO
Actinium Pharmaceuticals (ATNM) announced that the Canadian Intellectual Property Office, or CIPO, has issued notices of allowance for two patent applications spanning the company’s Actimab-A and Ioma...
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Together the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwide NEW YORK, May 2...
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will p...
NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies
BURLINGTON, Mass. & BELOIT, Wis.--(BUSINESS WIRE)--Partnership combines NorthStar's commercial-scale radioisotope production capabilities with QSA Global's expertise in management of Radium-226.
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Actinium Pharmaceuticals Quarterly report: Q1 2026
Actinium Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 8, 2026.
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its development as a mutation-agnostic therapy in settings whereresistance to EGFR- and KRAS-targeted a...
Actinium presents data from Actimab-A studies at AACR
Actinium Pharmaceuticals (ATNM) highlighted data presented at the American Association for Cancer Research, or AACR, Annual Meeting supporting transcriptional reprogramming as a central mechanism driv...
Actinium presents preclinical results for ATNM-400 at AACR
Actinium Pharmaceuticals (ATNM) announced preclinical results for ATNM-400 across prostate, lung, and breast cancer models presented at the American Association for Cancer Research, or AACR, Annual Me...
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies inc...
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential In prostate cancer, ATNM-400 demonstrates efficacy across bo...
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company, today announced that it received notice of the U.S. Food & Drug Administration's...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
New data underscoring the potential of ATNM-400 as a first-in-class Ac-225 radioconjugate with broad pan-tumor efficacy across multiple solid tumor models Actimab-A demonstrates mutation-agnostic eff...